Skip to main content
Inflammatory Bowel Diseases logoLink to Inflammatory Bowel Diseases
. 2022 Apr 2;28(10):e143. doi: 10.1093/ibd/izac066

Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial

Wenhui Zhang 1,#,, Astrid Scalori 2,#, Franklin Fuh 3, Jacqueline McBride 4, Gaohong She 5, Jaroslaw Kierkus 6, Bartosz Korczowski 7, Regan Li 8, Mariam Abouhossein 9, Alysha Kadva 10,2, K T Park 11, Meina Tao Tang 12,2
PMCID: PMC9527608  PMID: 35366308

In the originally published version of this manuscript, there was an error in the seventh author’s name. The seventh author’s name should read: “Bartosz Korczowski” instead of “Bartosz Korczowksi”. This error has been corrected.

Contributor Information

Wenhui Zhang, Genentech, Inc., South San Francisco, CA, USA.

Astrid Scalori, Roche Products Limited, Welwyn Garden City, United Kingdom.

Franklin Fuh, Genentech, Inc., South San Francisco, CA, USA.

Jacqueline McBride, Genentech, Inc., South San Francisco, CA, USA.

Gaohong She, Genentech, Inc., South San Francisco, CA, USA.

Jaroslaw Kierkus, Children’s Memorial Health Institute, Warsaw, Poland.

Bartosz Korczowski, University of Rzeszów, Rzeszów, Poland.

Regan Li, Roche Products Limited, Welwyn Garden City, United Kingdom.

Mariam Abouhossein, Genentech, Inc., South San Francisco, CA, USA.

Alysha Kadva, Genentech, Inc., South San Francisco, CA, USA.

K T Park, Genentech, Inc., South San Francisco, CA, USA.

Meina Tao Tang, Genentech, Inc., South San Francisco, CA, USA.


Articles from Inflammatory Bowel Diseases are provided here courtesy of Oxford University Press

RESOURCES